Efficient analysis of time-to-event endpoints when the event involves a continuous variable crossing a threshold

*Journal of Statistical Planning and Inference* 2020; 208:119-29

Controlling type I error rates in multi-arm clinical trials: A case for the false discovery rate

*Pharmaceutical Statistics* 2020

Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial

*medRxiv* 2020

Developing a predictive signature for two trial endpoints using the cross-validated risk scores method

*arXiv* 2020; arXiv:2007.01680

A review of Bayesian perspectives on sample size derivation for confirmatory trials

*arXiv* 2020; arXiv:2006.15715

Including non-concurrent control patients in the analysis of platform trials: Is it worth it?

*BMC Medical Research Methodology* 2020; 20:165

Graphical approaches for the control of generalised error rates

*Statistics in Medicine* 2020

The Adaptive designs CONSORT Extension (ACE) statement: A checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design

*BMJ* 2020; 369:m115

Analysis of responder-based endpoints: improving power through utilising continuous components

*Trials* 2020; 21:427

Efficient adaptive designs for clinical trials of interventions for COVID-19

*arXiv* 2020; arXiv:2005.13309